Data published by the French Medicines Safety Agency has shown 43 cases of cardiac incidents related to hydroxychloroquine, which highlights the risk of providing unproven treatments to COVID-19 patients.
“This initial assessment shows that the risks, particularly cardiovascular, associated with these treatments are very present and potentially increased in COVID-19 patients. Almost all of the reports come from health facilities, “the agency said. “These drugs should only be used in hospitals, under close medical supervision.”
France has recorded 100 health incidents and four deaths related to experimental drugs for people with coronavirus since the end of March. Three other patients had to be resuscitated and 82 incidents were deemed “serious”.
The incidents were about equally divided between hydroxychloroquine and the anti-HIV antivirals lopinavir-ritonavir.
The report comes as Trump repeatedly touts hydroxychloroquine as a possible treatment for coronaviruses, calling the drug a possible “game changer”.
However, health officials have expressed concerns about the drug, saying there is no solid evidence that it can be used for COVID-19.
“We have to be careful not to take this majestic leap to assume that this is a knockout drug. We still have to do the kind of studies that definitely prove if an intervention is really safe and effective, ” Anthony FauciAnthony FauciState AGs Highlights Racial Disparities In Early Data On Coronaviruses Night Health Care: Trump Officials Lay Foundation For May Reopening | Democrats step up talks with Mnuchin on next relief deal | Fauci says death toll could be around 60,000, Trump must minimize large-scale testing before reopening economy, the country’s leading infectious disease expert, said this week. “We don’t operate on what you feel, we operate on what the evidence and the data are. “